Find a Provider

Elizabeth Hexner, MD

Elizabeth Hexner, MD Physician

Assistant Professor of Medicine at the Hospital of the University of Pennsylvania

Dr. Hexner is a Penn Medicine employed physician.

Clinical Specialties


  • Medicine
    • Hematology
    • Medical Oncology

Programs & Services:

  • Cancer
    • Bone Marrow Transplant and Stem Cell Transplant Program
    • Leukemia
  • Hematology
    • Classical (Non-Malignant) Hematology Program

Board Certification:

  • Hematology, 2005
  • Medical Oncology, 2005

Conditions & Treatments:

  • Acute Lymphocytic Leukemia in Adults (ALL)
  • Acute Myeloid Leukemia (AML)
  • Blood Cancer
  • Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
  • Chronic Myeloid Leukemia (CML)
  • hematologic malignancies
  • Leukemia
  • Myeloproliferative Neoplams (MPN)

Clinical Interests

Myeloproliferative Neoplasms
Myelodysplastic Syndromes
Acute leukemia

Practice Locations and Appointments

Insurance Accepted

  • Aetna US Healthcare
  • Cigna
  • Cigna HealthSpring
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Medicaid
  • PA Medicare
  • Preferred Care
  • Rail Road Medicare / Palmetto GBA
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan

Education and Training

Medical School: Columbia University
Residency: NewYork-Presbyterian/Columbia University Medical Center
Fellowship: Hospital of the University of Pennsylvania


American Society of Hematology, International Department of Defense, National Racing to Register, National


Dr. Hexner is a Penn Medicine employed physician.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.


Research Interests:

Myeloproliferative Disorders
Umbilical Cord Blood Transplantation

Selected Publications:

Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M. W., Miller, C. B., Silver, R. T., Talpaz, M., Winton, E. F., Harvey, J. H., Arcasoy, M. O., Hexner, E. O., Lyons, R. M., Raza, A., Vaddi, K., Sun, W., Peng, W., Sandor, V., Kantarjian, H.: Three-year efficacy, overall survival, and safety of ruxolitinib therapy in patients with myelofibrosis from the COMFORT-I study Haematologica : 2015.

Hexner, E. O., Mascarenhas, J., Prchal, J., Roboz, G. J., Baer, M. R., Ritchie, E. K., Leibowitz, D., Demakos, E. P., Miller, C., Siuty, J., Kleczko, J., Price, L., Jeschke, G., Weinberg, R., Basu, T. T., Pahl, H. L., Orazi, A., Najfeld, V., Marchioli, R., Goldberg, J. D., Silverman, L. R., Hoffman, R.: Phase I dose escalation study of lestaurtinib in patients with myelofibrosis Leuk Lymphoma : 1-26,2015.

Reshef, R., Huffman, A. P., Gao, A., Luskin, M. R., Frey, N. V., Gill, S. I., Hexner, E. O., Kambayashi, T., Loren, A. W., Luger, S. M., Mangan, J. K., Nasta, S. D., Richman, L. P., Sell, M., Stadtmauer, E. A., Vonderheide, R. H., Mick, R., Porter, D. L.: High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning J Clin Oncol 33 (21): 2392-8,2015.

Bagley, S. J., Sehgal, A. R., Gill, S., Frey, N. V., Hexner, E. O., Loren, A. W., Mangan, J. K., Porter, D. L., Stadtmauer, E. A., Reshef, R., Luger, S. M.: Acute cholecystitis is a common complication after allogeneic stem cell transplantation and is associated with the use of total parenteral nutrition Biol Blood Marrow Transplant 21 (4): 768-71,2015.

van Zalen, S., Lombardi, A. A., Jeschke, G. R., Hexner, E. O., Russell, J. E.: AUF-1 and YB-1 independently regulate beta-globin mRNA in developing erythroid cells through interactions with poly(A)-binding protein Mech Dev 136 : 40-52,2015.

Bolanos-Meade, J., Logan, B. R., Alousi, A. M., Antin, J. H., Barowski, K., Carter, S. L., Goldstein, S. C., Hexner, E. O., Horowitz, M. M., Lee, S. J., Levine, J. E., MacMillan, M. L., Martin, P. J., Mendizabal, A. M., Nakamura, R., Pasquini, M. C., Weisdorf, D. J., Westervelt, P., Ho, V. T.: Phase III clinical trial steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute graft-versus-host disease: BMT CTN 0802 Blood : 2014.

Tong, Q., He, S., Xie, F., Mochizuki, K., Liu, Y., Mochizuki, I., Meng, L., Sun, H., Zhang, Y., Guo, Y., Hexner, E., Zhang, Y.: Ezh2 Regulates Transcriptional and Posttranslational Expression of T-bet and Promotes Th1 Cell Responses Mediating Aplastic Anemia in Mice J Immunol : 2014.

Hexner E, Roboz G, Hoffman R, Luger S, Mascarenhas J, Carroll M, Clementi R, Bensen-Kennedy D, and Moliterno A.: Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with the JAK2-V617F mutation Br J Haematol 164 : 83–93,2014.

Reshef, R., Hexner, E. O., Loren, A. W., Frey, N. V., Stadtmauer, E. A., Luger, S. M., Mangan, J. K., Gill, S. I., Vassilev, P., Lafferty, K. A., Smith, J., Van Deerlin, V. M., Mick, R., Porter, D. L.: Early Donor Chimerism Levels Predict Relapse and Survival after Allogeneic Stem Cell Transplantation with Reduced-Intensity Conditioning Biol Blood Marrow Transplant : 2014.

Babushok, D. V., Cardamone, D., Rulander, N., Master, S. R., Hexner, E. O.: A Common, Under-Recognized Cause of Elevated Serum Erythropoietin Am J Med : 2014.

Academic Contact Info

Perelman Center for Advanced Medicine
2 West Pavilion
3400 Civic Center Boulevard

Philadelphia, PA 19104
Phone: (215) 614-1847
Fax: (215) 615-5888
Patient appointments: 800-789-PENN (7366)

Related Links